Amycretin turned up in a lot of headlines because of one number: in an early trial, people on the highest dose lost roughly a quarter of their body weight. That's a genuinely eye-catching result. It's also an early result, from a small trial, for a drug nobody can legally prescribe yet. Both halves of that are true at once, and this page is about keeping them together.
What amycretin actually is
Amycretin (lab code NNC0487-0111) is a peptide — a short chain of amino acids, which are the tiny building blocks that make up protein. It's man-made, and it's being developed by Novo Nordisk, the Danish company behind Ozempic and Wegovy.
The interesting part is its design. An agonist is something that switches a receptor on — think of a key fitting a lock. Most weight-loss drugs are one key for one lock. Amycretin is one key cut to fit two:
- GLP-1 — the 'I'm full' signal your gut sends after a meal. Switching it on curbs appetite and slows how fast food leaves your stomach. This is the same target as semaglutide, the drug in Ozempic and Wegovy.
- Amylin — a hormone your pancreas releases alongside insulin when you eat. It also helps you feel full and tells your brain the meal is over. It's a separate signal from GLP-1, working through a different route.
Researchers call this a unimolecular co-agonist: "unimolecular" just means it's all one molecule rather than two drugs mixed together. That's the difference between amycretin and something like CagriSema, which pairs two separate peptides (cagrilintide and semaglutide) in one injection. Same basic idea — hit two appetite signals instead of one — but amycretin does it with a single designed molecule.
The tablet angle
One thing that made amycretin stand out early is that Novo Nordisk tested it as a tablet you swallow, not just an injection. Peptides are normally destroyed by your stomach, which is why most of these drugs are injected — so a version that survives being swallowed is a real technical achievement. Both forms have been through human trials, and the injected form is the one that carried through to the big final-stage program.
What it's studied for
- Obesity and weight loss — the main focus, and the target of the large trials now running
- Type 2 diabetes — a condition where blood sugar stays too high
- Conditions that travel with obesity — the current trial program also covers knee osteoarthritis, obstructive sleep apnea, and heart failure. None of those are settled questions.
What the evidence really shows
This is a case where the evidence is real but early — and the gap between those two words matters.
| Study | What it tested | What it found |
|---|---|---|
| First-in-human Phase 1 (published in The Lancet, 2025) | 144 adults with overweight or obesity, testing the oral tablet form, against a placebo (a dummy treatment) | Side effects were all mild or moderate, mostly gut-related, and got more common at higher doses. This trial was mainly about safety, not weight loss. |
| Phase 1b/2a (published in The Lancet, 2025) | 125 adults with overweight or obesity, testing the injected form for up to 36 weeks, against placebo | Substantial weight loss versus placebo across every dose group — the highest group averaged about 24% at 36 weeks. Gut side effects were frequent. A large number of people dropped out of the trial. |
| Phase 3 'AMAZE' program (running now) | Thousands of people across trials in obesity, type 2 diabetes, sleep apnea, knee osteoarthritis and heart failure — including one head-to-head against semaglutide | Not finished. Most of these trials won't report until 2028 or later. |
The honest read: 125 people for 36 weeks is a small, short study, and it was designed to check safety and find a workable dose, not to prove the drug works. Impressive numbers out of a trial that size are a reason to run bigger trials — which is exactly what's happening now — not a reason to treat the question as answered. The Phase 3 program is what will actually settle whether amycretin works, how well, and at what cost in side effects.
And those side effects aren't a footnote. Across both published trials, gut problems were the most common issue — nausea, vomiting, that whole family. Most were mild to moderate. But in the injection trial a lot of participants left before the end, and while many of those exits were for reasons unrelated to side effects, a high dropout rate makes any result harder to read with confidence.
What the research points to
- Two published human trials in a top-tier medical journal — real data, not hype
- Large weight loss versus placebo in an early injection trial
- A sound scientific idea: two separate fullness signals, one molecule
- A genuine technical feat — a peptide that survives being swallowed
- Enough promise that a major drug company committed to a full Phase 3 program
What it does NOT prove
- That it's a proven or approved weight-loss medicine — it's approved nowhere
- That the early weight-loss numbers will hold up in large trials; they often shrink
- That its long-term safety is established — 36 weeks in 125 people can't show that
- That it beats semaglutide or tirzepatide — the head-to-head trial hasn't reported
- That 'research chemical' versions online are the real, quality-checked drug
Who talks about it — and why to be careful
Amycretin gets discussed the way most pipeline weight-loss drugs do: as the next big thing, usually with that 24% figure detached from the trial it came from. Grey-market sellers pick up that momentum fast, and a drug that isn't approved anywhere is an easy thing to fake — there's no legitimate version to compare a counterfeit against. The people taking amycretin safely right now are volunteers in monitored trials with a research team watching their bloodwork. That is not the same activity as buying a vial online.
What this does not mean
- This does not mean amycretin is a proven or approved weight-loss medicine — it isn't approved anywhere, and its large trials aren't finished.
- This does not mean the early weight-loss numbers are what you'd get — they came from a small, short, early trial and may not hold up.
- This does not mean it's safe to buy and use; unregulated products aren't the trial drug and aren't checked for purity, strength, or safety.
- This is general education, not medical advice or a recommendation to use amycretin.